The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Drug discovery beyond the ‘rule-of-five’
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Natural products as sources of new drugs over the last 25 years
Newman, D. J., & Cragg, G. M. (2007) · Journal of Natural Products · doi:10.1021/np068054v · Cited by 5,517
DrugBank: a comprehensive resource for in silico drug discovery and exploration
Wishart, D. S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj067 · Cited by 3,892
How many drug targets are there?
Overington, J. P., Al-Lazikani, B., & Hopkins, A. L. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2199 · Cited by 3,505
Polyketide biosynthesis: a millennium review
Staunton, J., & Weissman, K. J. (2001) · Natural Product Reports · doi:10.1039/a909079g · Cited by 1,641
A decade of fragment-based drug design: strategic advances and lessons learned
Hajduk, P. J., & Greer, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2220 · Cited by 1,064
Benner, S. A., & Sismour, A. M. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1637 · Cited by 834
The Renaissance of Natural Products as Drug Candidates
Paterson, I., & Anderson, E. A. (2005) · Science · doi:10.1126/science.1116364 · Cited by 559
Koch, M. A., Schuffenhauer, A., Scheck, M., Wetzel, S., Casaulta, M., Odermatt, A., Ertl, P., & Waldmann, H. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503647102 · Cited by 544
Ligand efficiency indices as guideposts for drug discovery
Abad-Zapatero, C., & Metz, J. T. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03386-6 · Cited by 527
Jiang, S., Lin, K., Strick, N., & Neurath, A. R. (1993) · Nature · doi:10.1038/365113a0 · Cited by 508
Targeting Tyrosine Kinases in Cancer: The Second Wave
Baselga, J. (2006) · Science · doi:10.1126/science.1125951 · Cited by 478
Macrolide antibiotics. Chemistry, biology, and practice
Nagel, A. A. (1985) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.2600740930 · Cited by 475
The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin.
Schwecke, T., Aparicio, J. F., Molnár, I., König, A., Khaw, L. E., Haydock, S. F., Oliynyk, M., Caffrey, P., Cortés, J., & Lester, J. B. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.17.7839 · Cited by 445
Development trends for monoclonal antibody cancer therapeutics
Reichert, J. M., & Valge-Archer, V. E. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2241 · Cited by 389
Drug research: myths, hype and reality
Kubinyi, H. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1156 · Cited by 348
Studies Leading to Potent, Dual Inhibitors of Bcl-2 and Bcl-xL
Bruncko, M., Oost, T. K., Belli, B. A., Ding, H., Joseph, M. K., Kunzer, A., Martineau, D., McClellan, W. J., Mitten, M., Ng, S.-C., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm061152t · Cited by 304
Macrolide antibiotics : chemistry, biology, and practice
大村, 智. (2002) · Academic Press eBooks · Cited by 207
The therapeutic antibodies market to 2008
Pavlou, A. K., & Belsey, M. J. (2005) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2004.11.007 · Cited by 153
Synthesis and biological activities of novel 17-aminogeldanamycin derivatives
Tian, Z., Liu, Y., Zhang, D., Wang, Z., Dong, S. D., Carreras, C. W., Zhou, Y., Rastelli, G., Santi, D. V., & Myles, D. C. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.07.053 · Cited by 151
Properties and Architecture of Drugs and Natural Products Revisited
Grabowski, K., & Schneider, G. (2007) · Current Chemical Biology · doi:10.2174/2212796810701010115 · Cited by 132
Enfuvirtide, the first fusion inhibitor to treat HIV infection.
Poveda, E., Briz, V., & Soriano, V. (2005) · PubMed · Cited by 112
Direct thrombin inhibitors – a survey of recent developments
Schwienhorst, A. (2006) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-006-6219-z · Cited by 99
Targeting mTOR for Cancer Treatment
Rubio‐Viqueira, B., & Hidalgo, M. M. (2006) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-5133-3_24 · Cited by 71
2006 drug approvals: finding the niche
Owens, J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2247 · Cited by 59
Rapamycin biosynthesis: elucidation of gene product function
Gregory, M. A., Hong, H., Lill, R. E., Gaisser, S., Petković, H., Low, L., Sheehan, L. S., Carletti, I., Ready, S. J., Ward, M. J., et al. (2006) · Organic & Biomolecular Chemistry · doi:10.1039/b608813a · Cited by 48
Self-citationWilkinson, B., Gregory, M. A., Moss, S. J., Carletti, I., Sheridan, R., Kaja, A. L., Ward, M., Olano, C., Méndez, C., Salas, J. A., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.073 · Cited by 47
Self-citationGregory, M. A., Gaisser, S., Lill, R. E., Hong, H., Sheridan, R., Wilkinson, B. M., Petković, H., Weston, A. J., Carletti, I., Lee, H., et al. (2004) · Angewandte Chemie International Edition · doi:10.1002/anie.200453764 · Cited by 43
Self-citationTargeted therapeutics for multiple myeloma: The arrival of a risk-stratified approach
Fonseca, R., & Stewart, A. K. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0620 · Cited by 23
Progress in identifying peptides and small-molecule inhibitors targeted to gp41 of HIV-1
Debnath, A. K. (2006) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.15.5.465 · Cited by 21
Protein Structure Similarity Clustering: Dynamic Treatment of PDB Structures Facilitates Clustering
Charette, B. D., MacDonald, R. G., Wetzel, S., Berkowitz, D. B., & Waldmann, H. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602125 · Cited by 20
Brain-selective mTOR inhibitors as potential therapeutics for glioblastoma multiforme
Sheridan, R., Gregory, M. A., Petković, H., Gaisser, S., Lill, R. E., Ward, M. J., Kaja, A. L., Beckman, C. H., Challis, I. R., Moss, S. J., et al. (2006) · Repository of the University of Ljubljana (University of Ljubljana) · Cited by 1
Self-citation
Cited by
Pires, D. E. V., Blundell, T. L., & Ascher, D. B. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00104 · Cited by 5,716
Natural products in drug discovery
Harvey, A. L. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.07.004 · Cited by 1,832
Concepts of Artificial Intelligence for Computer-Assisted Drug Discovery
Yang, X., Wang, Y., Byrne, R., Schneider, G., & Yang, S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00728 · Cited by 1,022
Oral Druggable Space beyond the Rule of 5: Insights from Drugs and Clinical Candidates
Doak, B. C., Over, B., Giordanetto, F., & Kihlberg, J. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2014.08.013 · Cited by 835
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Metadata
- Authors
- Zhang, M.-Q., & Wilkinson, B.
- Venue
- Current Opinion in Biotechnology
- Publisher
- Elsevier BV
- Published
- 2007-12
- Volume
- 18
- Issue
- 6
- Pages
- 478-488
- ISSN
- 0958-1669 (ISSN-L)
- OpenAlex
- W2008059340
- Cited by
- 418
- References
- 33
- FWCI
- 0.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.